IDO1 and neoplasm: The increase in tumor cell lysis observed in the study reported here after CTL stimulation with epacadostat-treated DCs, and the potentially increased immunogenicity of tumor cells observed after IDO-inhibitor treatment, thus provide a rationale for combination therapy of epacadostat with cancer vaccines able to induce T-cell anti-tumor activity.